Evidence map›Paper›PMID 24760882›Full record

ArticleJournal of virology2014

Tumor suppressor cylindromatosis (CYLD) controls HIV transcription in an NF-κB-dependent manner.

Lara Manganaro, Lars Pache, Tobias Herrmann, John Marlett, Young Hwang, Jeffrey Murry, Lisa Miorin, Adrian T Ting, Renate König, Adolfo García-Sastre and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Barriers for HIV Cure: The Latent Reservoir.AIDS research and human retroviruses · 2018
    Review
  11. Review
  12. HIV-1 Infection of Primary CD4Journal of virology · 2018
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. CYLD-mediated signaling and diseases.Current drug targets · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Lara ManganaroDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Lars PacheInfectious and Inflammatory Disease Center, Sanford-Burnham Medical Research Institute, La Jolla, California, USA.
Tobias HerrmannDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA Institute of Biochemistry, Goethe University, Frankfurt, Germany.
John MarlettNomis Center for Immunobiology and Microbial Pathogenesis, The Salk Institute for Biological Studies, La Jolla, California, USA.
Young HwangDepartment of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Jeffrey MurryNomis Center for Immunobiology and Microbial Pathogenesis, The Salk Institute for Biological Studies, La Jolla, California, USA.
Lisa MiorinDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Adrian T TingImmunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Renate KönigInfectious and Inflammatory Disease Center, Sanford-Burnham Medical Research Institute, La Jolla, California, USA Research Group "Host-Pathogen Interactions," Paul-Ehrlich-Institut, Langen, Germany.
Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Frederic D BushmanDepartment of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Sumit K ChandaInfectious and Inflammatory Disease Center, Sanford-Burnham Medical Research Institute, La Jolla, California, USA.
John A T YoungNomis Center for Immunobiology and Microbial Pathogenesis, The Salk Institute for Biological Studies, La Jolla, California, USA.
Ana Fernandez-SesmaDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Viviana SimonDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA viviana.simon@mssm.edu.
Icahn School of Medicine at Mount Sinai · USSalk Institute for Biological Studies · USSanford Burnham Prebys Medical Discovery Institute · USUniversity of Pennsylvania · USGoethe University Frankfurt · DEPaul Ehrlich Institut · DE

Funding

Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ROBERT GROSS · 1999 to 2026
$78.6M
Molecular Virology and Systems Biology Screening CoreP01AI090935 · NIAID · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI YOUNG, JOHN A T · 2010 to 2014
$20.4M
THE ROLE OF ICSBP IN MUCOSAL IMMUNE RESPONSEP01DK072201 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HARPAZ, NOAM · 2006 to 2015
$14.6M
Favored Sites for HIV Integration in the Human GenomeR01AI052845 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI BUSHMAN, FREDERIC D · 2002 to 2017
$5.6M
GAS Switch from Colonizing Bacterium to Invasive PathogenR01AI077780 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NIZET, VICTOR · 2008 to 2019
$3.8M
HIV Evolution Driven by Intracellular DefensesR01AI064001 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SIMON, VIVIANA A · 2005 to 2015
$3.8M
Massively Parallel Analysis of Integration in Therapeutic Gene TransferR01AI082020 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI BUSHMAN, FREDERIC D · 2009 to 2018
$3.5M
MODULATION OF INNATE AND ADAPTIVE IMMUNITY BY DENGUE VIRUSR01AI073450 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FERNANDEZ-SESMA, ANA · 2008 to 2017
$3.3M
Cellular factors in gammaretrovirus replicationR01AI072645 · NIAID · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI YOUNG, JOHN A T · 2007 to 2011
$2.2M
Genomic Determinants of Intrinsic Antiviral Host DefensesR01AI089246 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SIMON, VIVIANA A · 2010 to 2014
$2.1M
NIAID NIH HHS 1R01AI073450NIAID NIH HHS AI052845NIAID NIH HHS AI064001NIAID NIH HHS AI082020NIAID NIH HHS AI089246NIAID NIH HHS AI72645NIAID NIH HHS AI77780NIAID NIH HHS P01 AI090935NIAID NIH HHS P30 AI045008NIAID NIH HHS R01 AI052845NIAID NIH HHS R01 AI064001NIAID NIH HHS R01 AI072645NIAID NIH HHS R01 AI073450NIAID NIH HHS R01 AI077780NIAID NIH HHS R01 AI082020NIAID NIH HHS R01 AI089246NIDDK NIH HHS P01 DK072201
6 · The paper itself

Abstract

unlabelledCharacterizing the cellular factors that play a role in the HIV replication cycle is fundamental to fully understanding mechanisms of viral replication and pathogenesis. Whole-genome small interfering RNA (siRNA) screens have identified positive and negative regulators of HIV replication, providing starting points for investigating new cellular factors. We report here that silencing of the deubiquitinase cylindromatosis protein (CYLD), increases HIV infection by enhancing HIV long terminal repeat (LTR)-driven transcription via the NF-κB pathway. CYLD is highly expressed in CD4(+) T lymphocytes, monocyte-derived macrophages, and dendritic cells. We found that CYLD silencing increases HIV replication in T cell lines. We confirmed the positive role of CYLD silencing in HIV infection in primary human CD4(+) T cells, in which CYLD protein was partially processed upon activation. Lastly, Jurkat T cells latently infected with HIV (JLat cells) were more responsive to phorbol 12-myristate 13-acetate (PMA) reactivation in the absence of CYLD, indicating that CYLD activity could play a role in HIV reactivation from latency. In summary, we show that CYLD acts as a potent negative regulator of HIV mRNA expression by specifically inhibiting NF-κB-driven transcription. These findings suggest a function for this protein in modulating productive viral replication as well as in viral reactivation. IMPORTANCE: HIV transcription is regulated by a number of host cell factors. Here we report that silencing of the lysine 63 deubiquitinase CYLD increases HIV transcription in an NF-κB-dependent manner. We show that CYLD is expressed in HIV target cells and that its silencing increases HIV infection in transformed T cell lines as well as primary CD4(+) T cells. Similarly, reactivation of latent provirus was facilitated in the absence of CYLD. These data suggest that CYLD, which is highly expressed in CD4(+) T cells, can control HIV transcription in productive infection as well as during reactivation from latency.

Indexed as

Transcription, GeneticBlotting, WesternCD4-Positive T-LymphocytesDeubiquitinating Enzyme CYLDFluorescent Antibody TechniqueGene Expression Regulation, ViralHEK293 CellsHIV-1HIV InfectionsHIV Long Terminal RepeatHumansJurkat CellsMacrophagesNF-kappa BReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionCYLD protein, humanDeubiquitinating Enzyme CYLDNF-kappa BRNA, MessengerRNA, Small InterferingTumor Suppressor Proteins

Identifiers

PMID24760882
PMCPMC4054419
OpenAlexW2100378148

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.